Butyricicoccus spp. are anaerobic, Gram-positive bacteria found in the human gut. They play a vital role in producing butyrate, a short-chain fatty acid essential for gut health.
By metabolizing dietary fibers and amino acids, these bacteria help maintain the gut barrier, reduce inflammation, and promote overall gut health. Their abundance is notably reduced in conditions like ulcerative colitis and chronic kidney disease.
Butyricicoccus spp. is a genus of anaerobic, Gram-positive bacteria found in the human gut. Part of the Firmicutes phylum, it is a commensal bacterium, meaning it normally coexists with the human body without causing harm.
One of its most important functions is the production of butyrate, a short-chain fatty acid (SCFA) essential to gut health. These bacteria metabolize dietary fibers and amino acids to generate butyrate, which serves as an energy source for colonocytes, stabilizes the gut barrier, and reduces permeability by regulating tight junction proteins.
Butyricicoccus spp. abundance is reduced in conditions like ulcerative colitis (UC) and chronic kidney disease (CKD), with research showing that a decrease in Butyricicoccus correlates with increased expression of claudin-1, a tight junction protein, which may be associated with inflammation.
Research suggests that Butyricicoccus and its metabolites, such as butyrate, could help reverse inflammation-induced damage and maintain gut barrier function, offering potential therapeutic benefits for conditions like UC and CKD.
One notable species, Butyricicoccus pullicaecorum, has been studied as a potential next-generation probiotic. Research has demonstrated that B. pullicaecorum is safe, well-tolerated, and does not disrupt the gut microbiota or metabolic activity, making it a promising candidate for promoting gut health.
While these effects cannot definitively be extrapolated to humans, animal studies have shown that B. pullicaecorum can reduce colorectal cancer progression and enhance survival, possibly through its effects on short-chain fatty acid transporters. The bacterium’s stable shelf life also supports its viability as a probiotic.
Butyrate plays a key role in maintaining gut health. It provides energy to colon cells, supports the gut barrier by regulating tight junction proteins, and reduces gut inflammation by limiting pro-inflammatory cytokines.
Butyrate also helps balance the gut microbiome by promoting beneficial microbes and producing antimicrobial substances. It has therapeutic potential for conditions like inflammatory bowel disease and colorectal cancer, and its effects extend to immune modulation and cancer prevention.
Dietary interventions can promote butyrate production, supporting gut health.
Assessment of Butyricicoccus spp. levels may be useful in several clinical scenarios:
Patients with suspected gut dysbiosis or an imbalance in gut bacteria may benefit from testing Butyricicoccus spp. levels as part of a broader microbiome analysis.
For patients with conditions like IBD or IBS, where Butyricicoccus spp. levels may be altered, evaluating these levels can provide insights into disease mechanisms and may inform treatment strategies.
Butyricicoccus spp. abundance may be investigated in various studies exploring links between the microbiome and conditions such as metabolic syndrome, autoimmune diseases, and even mental health disorders.
The following section outlines important testing and interpretation information:
Butyricoccus spp. is typically tested using stool samples, which can be conveniently collected at home. Patients are advised to avoid medications and supplements, including probiotics, before collection. Always follow the lab company's recommendations regarding preparation and sample collection.
The following information is generally accepted regarding microbiome analysis and testing; always consult the laboratory company used for their recommendations.
The optimal relative abundance of Butyricoccus spp. in the gut microbiome can vary based on individual factors such as age, diet, and lifestyle.
Generally, normal reference ranges for microbiome species are reported as a balanced abundance, with excessively high or low levels being out of range. The testing laboratory used should provide specific reference ranges.
High levels are associated with:
High levels of Butyricicoccus spp. are generally seen as a sign of healthy gut function, indicating enhanced butyrate production and a stronger gut barrier.
Higher levels often correlate with reduced gut inflammation, which may support gut health in conditions like IBD.
Adequate levels may help maintain proper digestion and movement through the intestines.
Low levels of Butyricoccus spp. may indicate:
Low levels of Butyricicoccus spp. may indicate gut dysbiosis, where harmful bacteria outnumber beneficial ones. Comprehensive testing can assess for levels of harmful bacteria in the microbiome.
A lack of Butyricicoccus spp. could result in less butyrate production, contributing to inflammation in the gut which is a hallmark of conditions such as inflammatory bowel disease.
Low levels of Butyricicoccus spp. have been associated with chronic kidney disease.
When levels are low, clinicians should consider a comprehensive analysis of the gut microbiome to understand the full scope of the dysbiosis and guide treatment options.
Click here to compare testing options for various stool assessment panels and order testing.
Bojović, K., Ignjatović, Ð. -d ica, Soković Bajić, S., Vojnović Milutinović, D., Tomić, M., Golić, N., & Tolinački, M. (2020). Gut Microbiota Dysbiosis Associated With Altered Production of Short Chain Fatty Acids in Children With Neurodevelopmental Disorders. Frontiers in Cellular and Infection Microbiology, 10. https://doi.org/10.3389/fcimb.2020.00223
Chang, S. C., Shen, M. H., Liu, C. Y., Pu, C. M., Hu, J. M., & Huang, C. J. (2020). A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine-associated colorectal cancer. Oncology letters, 20(6), 327. https://doi.org/10.3892/ol.2020.12190
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., & Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of lipid research, 54(9), 2325–2340. https://doi.org/10.1194/jlr.R036012
Devriese, S., Eeckhaut, V., Annelies Geirnaert, Van, L., Pieter Hindryckx, Van, T., Filip Van Immerseel, Ducatelle, R., Martine De Vos, & Laukens, D. (2016). Reduced Mucosa-associated Butyricicoccus Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression. Journal of Crohn’s and Colitis, 11(2), 229–236. https://doi.org/10.1093/ecco-jcc/jjw142
Eeckhaut, V., Machiels, K., Perrier, C., Romero, C., Maes, S., Flahou, B., Steppe, M., Haesebrouck, F., Sas, B., Ducatelle, R., Vermeire, S., & Van Immerseel, F. (2012). Butyricicoccus pullicaecorumin inflammatory bowel disease. Gut, 62(12), 1745–1752. https://doi.org/10.1136/gutjnl-2012-303611
Gryp, T., Faust, K., Van Biesen, W., Huys, G. R. B., Verbeke, F., Speeckaert, M., Raes, J., Vaneechoutte, M., Joossens, M., & Glorieux, G. (2021). Gut Microbiome Profiling Uncovers a Lower Abundance of Butyricicoccus in Advanced Stages of Chronic Kidney Disease. Journal of personalized medicine, 11(11), 1118. https://doi.org/10.3390/jpm11111118
Hodgkinson, K. M., Faiha El Abbar, Peter Allan Dobranowski, Manoogian, J., Butcher, J., Figeys, D., Mack, D. R., & Alain Stintzi. (2023). Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clinical Nutrition, 42(2), 61–75. https://doi.org/10.1016/j.clnu.2022.10.024
Leen Boesmans, Mireia Valles-Colomer, Wang, J., Eeckhaut, V., Falony, G., Ducatelle, R., Filip Van Immerseel, Raes, J., & Verbeke, K. (2018). Butyrate Producers as Potential Next-Generation Probiotics: Safety Assessment of the Administration of Butyricicoccus pullicaecorum to Healthy Volunteers. 3(6). https://doi.org/10.1128/msystems.00094-18
Singh, V., Lee, G., Son, H., Koh, H., Kim, E. S., Unno, T., & Shin, J. H. (2023). Butyrate producers, "The Sentinel of Gut": Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Frontiers in microbiology, 13, 1103836. https://doi.org/10.3389/fmicb.2022.1103836